Saturday 17 October 2026
Export TRVI’s income statement to Excel — free account
Trevi Therapeutics, Inc.
TRVI Healthcare Biotechnology
In the quarter to June 2026, EPS fell 22.2% and free cash flow fell 73.8%, each against the same quarter a year earlier.
11.87
0.24
−1.98%
Follow TRVI
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | 2.65 | 1.33 | 0.66 | 0.46 | 0.97 | 1.27 | 3.47 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | 10.62 | 8.50 | 3.64 | 4.68 | 3.50 | 4.68 | 14.39 | |||||
| People | |||||||||||||||
| People | Employees | — | — | 16 | 17 | 22 | 24 | 25 | 25 | 26 | 34 | ||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (11) | (13) | (21) | (26) | (33) | (34) | (29) | (29) | (48) | (43) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (11) | (13) | (21) | (26) | (33) | (34) | (29) | (29) | (48) | (43) | |||||
| Depreciation | 0 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (0.42) | (30.55) | (46.91) | (2.28) | (1.81) | (1.49) | (0.45) | (0.29) | (0.47) | (0.32) | |||||
| Cash flow | (0.69) | (18.94) | (41.76) | (1.97) | (1.61) | (1.27) | (0.44) | (0.32) | (0.38) | (0.31) | |||||
| Capex | 0.00 | (0.03) | (0.36) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | (0.69) | (18.97) | (42.12) | (1.97) | (1.61) | (1.27) | (0.44) | (0.32) | (0.38) | (0.31) | |||||
| Book value | (1.08) | 35.10 | 14.26 | 4.65 | 1.51 | 0.75 | 1.66 | 0.83 | 0.98 | 1.36 | |||||
| Shares, m | 16 | 0 | 0 | 12 | 18 | 23 | 65 | 99 | 102 | 135 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (11) | (8) | (18) | (23) | (29) | (29) | (28) | (32) | (38) | (42) | ||||
| Capex | — | 0 | 0 | 0 | 0 | — | 0 | 0 | 0 | 0 | |||||
| Free cash flow | (11) | (8) | (18) | (23) | (29) | (29) | (28) | (32) | (38) | (42) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | (12) | 15 | 6 | 54 | 41 | 25 | 109 | 82 | 99 | 182 | ||||
| Total debt | 22 | 5 | 1 | 0 | 14 | 14 | 9 | 0 | — | — | |||||
| Net debt | 14 | (17) | (6) | (57) | (31) | (22) | (111) | (83) | (108) | (188) | |||||
| Shareholders’ equity | (17) | 15 | 6 | 55 | 27 | 17 | 107 | 83 | 100 | 183 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (43.83) | (81.86) | (156.18) | (75.87) | (61.15) | (79.29) | (36.10) | (27.37) | (47.84) | (28.10) | ||||
| ROIC | 0.00 | 0.00 | (8,102.11) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | 8.58 | 16.02 | 26.38 | 97.38 | (80.07) | (153.03) | (46.82) | (30.59) | (52.59) | (30.23) | |||||
Negative figures in brackets.
Charts ten years each
Trevi Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MESO Mesoblast Limited | $1.8B | — (loss-making) | — | −13.41% (below 0%: shrinking) | n/m | −89.23% (below 0%: shrinking) | (353.35%) | (909.40%) | Compare |
| URGN Urogen Pharma | $1.8B | — (loss-making) | — (loss-making) | +199.22% (above 0%: growing) | n/m | +17.26% (above 0%: growing) | 90.93% | 0.15% | Compare |
| XNCR Xencor, Inc. | $1.8B | — (loss-making) | — (loss-making) | +17.46% (above 0%: growing) | n/m | −52.91% (below 0%: shrinking) | 100.00% | (72.37%) | Compare |
| VIR Vir Biotechnology, Inc. | $1.8B | — (loss-making) | — (loss-making) | +19,582.54% (above 0%: growing) | n/m | +200.47% (above 0%: growing) | 100.00% | 30.75% | Compare |
| SEPN Septerna, Inc. | $1.8B | — (loss-making) | — (loss-making) | +22,375.63% (above 0%: growing) | n/m | −9.01% (below 0%: shrinking) | 100.00% | (62.95%) | Compare |
| TRVI Trevi Therapeutics, Inc. | $1.7B | — (loss-making) | — | — | n/m | −73.77% (below 0%: shrinking) | 0.00% | 0.00% | |
| BHVN Biohaven Ltd. | $1.7B | — (loss-making) | — (loss-making) | +131.43% (above 0%: growing) | n/m | +49.13% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NUVB Nuvation Bio Inc. | $1.7B | — (loss-making) | — (loss-making) | +555.64% (above 0%: growing) | n/m | +10.62% (above 0%: growing) | 70.11% | (161.06%) | Compare |
| ZBIO Zenas BioPharma, Inc. | $1.7B | — (loss-making) | — (loss-making) | — | n/m | −37.12% (below 0%: shrinking) | 100.00% | (10,765.90%) | Compare |
| Median of peers | $1.8B | — | — | +199.22% | — | +0.81% | 95.47% | (67.66%) |
Trevi Therapeutics, Inc. (TRVI) key facts
- Trevi Therapeutics, Inc. (TRVI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, TRVI traded at $11.87, a market capitalization of $1.7 billion.
- Return on equity was −30.2% and debt-to-equity 0.00.
Trevi Therapeutics, Inc. (TRVI) Latest News
No news at this impact. Lower the threshold for more.